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Andrea László, László Kalabay* and János NemcsikAbstract
Background: Lifestyle modifications including exercise are beneficial and fundamentally part of the therapy of
metabolic syndrome, although in most of the cases medical interventions are also required to reach the target
values in the laboratory parameters. Statin and fibrate combination therapy is considered to be safe and effective in
dyslipidaemia and metabolic syndrome. However, increased physical activity can enhance the statin and
fibrate-associated myopathy. Myositis and the rare but life-threatening rhabdomyolysis are causing a conflict
between exercise and statin-fibrate therapy, which is yet to be resolved.
Case presentation: We present a case of a 43-year-old Caucasian man with metabolic syndrome who had the
side-effect of exercise and drug-associated myositis. The patient had only transient moderate complaints and
rhabdomyolysis could be avoided with the one-month creatine kinase control, a test which is not recommended
routinely by the new guidelines.
Conclusions: We would like to turn the spotlight on the possible complications of statin-fibrate therapy and
exercise, when strict follow-up is recommended. In this condition high number of patients can be affected and the
responsibility of general practitioners is accentuated.
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Cardiovascular disease is the leading cause of death in
developed countries. In adults besides body mass index
above 30 kg/m2 or elevated waist circumference, the
clustered presence of 2 or more cardiovascular risk fac-
tors from among high triglyceride and fasting blood glu-
cose levels, low high-density lipoprotein cholesterol
(HDL-C), raised blood pressure and the presence of
treated hypertension or type 2 diabetes has been desig-
nated the “metabolic syndrome” (MetS) [1]. These com-
ponents are the principal risk factors in the development
of atherosclerosis and cardiovascular disease. Related to
this high risk status, the treatment of patients with MetS
is an important task of the basic healthcare.* Correspondence: kalasz@kut.sote.hu
Department of Family Medicine, Semmelweis University, Kútvölgyi str. 4,
Budapest 1125, Hungary
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reproduction in any medium, provided the orThere is substantial evidence that regular exercise has
beneficial effects in physical and mental health and con-
tributes to the primary and secondary prevention of car-
diovascular and several chronic diseases, like breast and
colon cancer or diabetes [2]. Exercise improves a variety
of lipid and lipoprotein variables [3] and is a fundamen-
tal part of the therapy of MetS.
The alternative of the lifestyle modifications is the use
of tablets. For the correction of lipid disorders in MetS,
recommendations, like the recent European guideline
(European Society of Cardiology and the European
Atherosclerosis Society (ESC/EAS 2011) [4]) aims a cer-
tain level of serum lipids. Not only statin or fibrate treat-
ment, but their combination may be also required to
achieve target lipid levels (cholesterol, LDL-C, triglyce-
rides, HDL-C), which appears to confer additional car-
diovascular risk – compared with LDL-C alone [5]. Thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and diabetes with the administration of fenofibrate be-
sides the statins [4].
Although the use of statins considered to be safe, some
studies suggest that the frequency of statin myopathy is
between 9% and 20% [6-8]. If muscle symptoms are ac-
companied by the elevation of creatine kinase (CK)
levels, the condition is known as myositis [9-11].
Rhabdomyolysis is the most serious side-effect of the
statin therapy, where renal insufficiency is present, as
well. However, in some studies this side effect was found
to be rare (affecting 0,1% of statin users) [12-15], and
moreover no cases of drug-related rhabdomyolysis were
reported in some follow-up studies [16,17]. Statins com-
bined with fibrate also increase the incidence of statin-
induced myopathies [11,18-20], suggested a 5.5-fold
greater elevation compared with statin use alone [21].
In addition, physical exercise can also influence the oc-
currence of myopathy in patients using statins and fibrates.
Muscle complaints may affect 25% of the statin users who
exercise [22], and the prevalence of this phenomenon is
75% among athletes who take the drug [23].
Although the new ESC guideline on dyslipidaemias is
expansively engaged in lifestyle modifications, it does
not focus on the problem of the elevated risk of myo-
pathy during statin-fibrate therapy and exercise [4]. This
condition is not mentioned as a recommended reason
for periodic CK control [4].
In our case report we present a patient with MetS who
took statin and fibrate therapy and started parallel exer-
cise leading to myositis with moderate symptoms but ex-
cessive CK elevation.
Case presentation
On routine laboratory examination dyslipidaemia was
found in a 43-year-old man without symptoms, who pre-
sented in our general practitioner praxis in October
2011. The patient was obese (body mass index 31.7 kg/m2,
waist circumference 104 cm), with the history of 25 pack-
year smoking and 2 units (20 ml) of alcohol intake per
week. His hypertension started 10 years ago and was con-
trolled with 2.5 mg nebivolol per day. He was a blue-collar
worker in a storehouse, and sometimes did manual work
(not every day and not exhausting).
His values were: total cholesterol 277.7 mg/dL, triglyce-
rides 448.2 mg/dL, HDL-C 36.7 mg/dl, fasting plasma glu-
cose level was 5.68 mmol/L. LDL-C could not have been
evaluated, because the elevated serum triglyceride level
disturbed the measurement. Based on data above, the pa-
tient fulfilled the requirements of MetS (central obesity,
raised serum triglycerides, reduced HDL-C, treated hyper-
tension and upper range of normal fasting glucose level
were present). Other parameters, like creatine kinase
(CK), aspartate transaminase (AST), alanine transaminase(ALT) and gamma glutamyl transpeptidase (GGT) were in
the normal range (117 U/l, 26 U/l, 23 U/l and 36 U/l,
respectively). Renal function (blood urea nitrogen: 7.6
mmol/l, serum creatinine: 97 μmol/L, glomerular filtration
rate: >60 ml/min) was also normal. Past medical history
included laparoscopic cholecystectomy in his 30s. From
family history hypertension, hypercholesterinaemia and
obesity of both parents must be mentioned. None of them
had any side effect for drug administration (both of them
took statins).
After informing the patient about his elevated cardio-
vascular risk, he ensured us to cooperate regarding tak-
ing the prescribed medications (except for aspirin,
because of bad family experience). About lifestyle modi-
fications he did not see possibilities for exercise because
of his exhausting job. On the other hand, about diet he
said, that he tried to decrease the calorie intake long
ago, but because of his manual work he often felt hungry
and required extra meals. He promised to keep this kind
of diet in the future as well, which apparently was not
enough. Due to the high triglycerides and lack of lifestyle
modification possibilities, 160 mg fenofibrate per day
was applied. The patient was also informed about the
possible side-effects of the lipid-lowering therapy. Be-
cause of smoking, varenicline therapy was prescribed as
well, as the patient previously failed to give up smoking
with lifestyle modifications and the use of nicotine
patch.
The patient came for one-month control without any
symptoms, and mentioned that he had begun taking va-
renicline only one week earlier. Laboratory parameters
revealed the efficacy of the therapy. Serum triglycerides
were reduced, but remained above the target level (349
mg/dL), CK was in the normal range (121 U/l), but cho-
lesterol showed further increase (310.5 mg/dL). Taking
the lipid levels and the high cardiovascular risk of the
patient due to MetS into consideration, 20 mg atorvasta-
tin per day was added to the therapy. Similarly, a control
laboratory test was set one month later.
The patient was also asymptomatic at the second con-
trol. This time both the values of triglycerides and chol-
esterol showed improvement, 154.1 and 249.8 mg/dL,
respectively. However, in the CK level a more than 150-
fold elevation was observed (18979 U/l). Kept on asking
the possible symptoms, the patient told us that he had
changed his mind about exercise and one week ago he
bought body-building equipment. After he worked out
with all kind of dumb-bells, he had moderate pain and
stiff feeling everywhere in his chest and in both arms
and legs and dark urine was observed parallel. The pain
lasted for three days, than the symptoms disappeared. At
the time of the control he had no muscle complaints.
He had stopped taking varenicline after 2 weeks, and
had taken the three types of medicines together (statin,
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smoke since then. The irregular moderate alcohol con-
sumption was continued during taking the prescribed
medications, as well.
The findings of the physical examinations were nor-
mal. The electrocardiography did not show any relevant
pathological abnormalities. Based on these data, the pa-
tient was sent to the emergency care unit of the territo-
rial hospital with the diagnosis of rhabdomyolysis. He
was admitted to the Department of Cardiology.
In the hospital on the day of admission in blood test
results ALT (131.5 U/l) and AST (247.7 U/l) were ele-
vated, while GGT remained in the normal range (38 U/l).
The lactate dehydrogenase (LDH) level was also increased,
463 U/l. Statin and fibrate medications were stopped, and
altogether 2 litres of Salsol infusion was administered. On
the next days CK showed decreasing tendency (5134,
1823 U/l), and reduction was observed in one of the levels
of liver transaminases (AST: 131.3; ALT: 95.5 U/l), and in
LDH (386 U/l). Serum cholesterol level remained elevated
(257.2 mg/dL), triglycerides reached the normal range
(151.5 mg/dL). Kidney function parameters did not show
any abnormalities, and the thyroid function test was also
normal (thyroid-stimulating hormone 1.42 μU/ml). As the
patient remained asymptomatic, and the laboratory con-
trols indicated improvement, he was discharged following
2 days of hospitalization. Strict alcohol abstinence, 180
grams/day carbohydrate diet with low fat and salt intake
were recommended at emission, completed with fish oil
capsules and dietary sources of omega-3 fatty acids. Future
contraindication of statin-fibrate combination therapy was
stated, and laboratory control was advised in two days.
The control showed further improvement in the levels
of transaminases, CK and LDH, but they were still moder-
ately elevated (AST 58.8 U/l, ALT 72.1 U/l, CK 526 U/l,
LDH 417 U/l). One month later the laboratory control
was repeated in our praxis: CK and transaminases were
normal, dyslipidaemia was reduced (total cholesterol and
triglycerides levels were 238.3 and 216.1 mg/dL, respect-
ively). Since that time the patient has been asymptomatic,
keeps diet, exercises regularly (with no marked CK eleva-
tion), takes 1 gram omega-3 fatty acid per day, and thanks
to the varenicline therapy he does not smoke.
The diagnosis of drug-induced myositis was reported
to the Hungarian National Institute of Pharmacy.
According to the recommendation of ESC/EASC guide-
line for the management of dyslipidaemias, it is always ap-
propriate to advise patients to engage in regular physical
exercise of moderate intensity [24]. Lifestyle modification
is recommended as the first step treating MetS, as well
[4]. In fact, physical activity is one of the most cost-
effective ways to prevent cardiovascular diseases.
However, lifestyle interventions considered being diffi-
cult to be maintained, and drugs are frequently prescribedas it is influenced by pharmaceutical industry pressure, as
well [25]. Moreover, statin therapy has been suggested to
be a fundamental tool of the prevention of coronary artery
disease [26]. There is a growing concern that this total
focus on statin use may distract attention from simple life-
style changes and also interfere with exercise [22,27].
In our patient fibrate and later statin-fibrate medica-
tions were initiated because of the limited lifestyle chan-
ging possibilities. However, the patient changed his mind
and started exercise which led to severe myositis but
only moderate symptoms.
Although the patient had been already on combination
therapy when the myositis started but the main cause of
it was probably the atrovastatin as compared with gemfi-
brozil, fenofibrate were found to be less prone to make
complications when used together with statins [28].
However, the pathophysiological role of fenofibrate or
the exaggerating effect in the extent of CK elevation can-
not be excluded.
Our case report shows the emerging problem of paral-
lel application of exercise and statin-fibrate therapy. Al-
though this problem is not new but still some questions
are opened. It is not clear, what kind of exercise is safe
and can be recommended besides statin-fibrate use. Es-
pecially prolonged exercise, like weight bearing and
those which require eccentric muscular contractions (for
example downhill treadmill walking) seem to exacerbate
muscle injury [29-32]. So far no study has addressed the
risk of exercise during statin and fibrate use or the pos-
sibly recommended type of gymnastics which are safe,
but still beneficial in this condition.
Amongst other possible pathophysiological factors the
moderate alcohol consumption of our patient probably
did not influence the exercise-induced statin-myopathy
as in low amounts (12.7-38.1 ml of ethanol per day in
men) it was not found to be harmful [24].
Another question arises whether the statin-fibrate
therapy-induced rhabdomyolysis could be connected to
varenicline intake. The theoretical background of this
interaction is based on the observation of Obrach et al.,
who found two metabolites in human excreta of vareni-
cline: one of them is the N-carbamoylglucuronide, cata-
lyzed by the UDP-glucuronosyltransferase-2B7 (UGT2B7)
[33]. Fenofibrate is also glucuronidated by this enzyme
[34]. Thus a varenicline-fenofibrate interaction is theoret-
ically possible. In our case, 3 weeks after starting the
fibrate therapy the patient began to take varenicline, and
one week later atorvastatin. He took altogether a 2-week
dose of varenicline where in the second week he took
fenofibrate and atorvastatin, as well. The symptoms
started two weeks after the stop of varenicline, so it prob-
ably had no role in the side effect.
Statin-fibrate combination should be prescribed with
caution to patients who also receive other drugs that are
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matic hydroxylation of nebivolol takes place in CYP 2D6
[35], a single nucleotid polymorphism of this type of
cytochrome enzyme (the presence of CYP 2D6*4 allele)
was also found to be associated with statin-induced
muscle effects [36]. Although interaction between statins
and nebivolol has not been published yet, nebivolol
might have influenced the development of rhabdomyoly-
sis in our patient. Unfortunately we did not have the
opportunity to check the presence of this CYP 2D6*4
phenotype in our patient.
According to the guidelines, although pre-treatment CK
level is required to be measured, routine monitoring of the
enzyme without symptoms of myopathy/rhabdomyolysis,
or risk factors is not necessary [4]. Furthermore, recent
studies have suggested, that routine examinations for side
effects are not cost-effective [10,37]. However, in our pa-
tient, who had no symptoms at the regular visits, the rou-
tine laboratory CK control indicated the severe myopathy
and with the urgent intervention the development of acute
renal failure and other severe complications could be pre-
vented. Based on our case, the control of CK should also
be added to lipid function control 4–6 weeks after the ini-
tiation of statin-fibrate combined therapy especially in
those patients who do exercise parallel.
Finally, we must mention some emerging critical
aspects of our medical attendance. With more impres-
sions, the patient might have been convinced about the
necessity of lifestyle modifications before the drug
administrations. Unfortunately the patients' attitude and
the insufficiency of time which can be expended for each
patient in the office of a general practitioner sometimes
limit our success. Secondly, fenofibrate was administered
first instead of atrovastatin. This choice also can be
debated, but we have chosen fibrate because of the
more, than 3-fold higher triglyceride and the moderately
elevated total cholesterol at the beginning. Third, unfor-
tunately at the first blood test LDL-cholesterol could not
have been evaluated because of the disturbing effect of
raised triglyceride. Later at the control blood tests only
total cholesterol was measured. LDL-cholesterol is an es-
sential parameter of cardiovascular risk stratification and
must be the part of the general laboratory protocol.
Conclusions
In conclusion, although fenofibrate and statin combi-
nation therapy is supposed to be safe, myopathy, myo-
sitis and rhabdomyolysis still can develop. Exercise, as a
part of lifestyle modifications can increase the risk of
muscle side effects besides drug therapy providing a
conflict between the two main therapeutic pathways of
MetS. Further studies are required to define the types of
exercise which are safe together with lipid lowering
medications. The incidental interaction of nebivolol withstatins or fibrates is also need to be clarified in the future.
Moreover, also by asymptomatic patients the one-month
CK control is important when exercise is present besides
statin-fibrate therapy. In our case this test prevented the
development of further serious complications.
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